Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence

Breast Cancer Research and Treatment

Volumn 47, Issue 1, 1998, Pages 9-16

  Kute, Timothy Edward ^a   Grøndahl Hansen, Jan ^b   Shao, Si Ming ^a   Long, Rena ^a   Russell, Greg ^a   Brünner, Nils ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b FINSEN LABORATORY   (Denmark)

Author keywords

Node negative; Prognostic markers; Protease inhibitors; Proteases

Indexed keywords

CATHEPSIN D; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CYTOSOL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CATHEPSIN D; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RISK; SURVIVAL RATE;

EID: 0031974329     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005882520982     Document Type: Article

References (22)

1. Schmitt M, Jänicke F, Graeff H: Proteases, matrix degradation & tumor cell spread. Fibrinolysis 6: 1-170, 1992
2. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829, 1990
3. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993
4. Jänicke F, Schmidt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208, 1993
5. Foekens JA, Schmitt M, Van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658, 1994
6. Rochefort H: Cathepsin D in breast cancer. Breast Cancer Res Treat 16: 3-13, 1990
7. Kute TE, Shao CM, Sugg NK, Long RT, Russell GB, Case LD: Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52: 5198-5203, 1992
8. Grøndahl-Hansen J, Peters HA, Van Putten WJ, Look MP, Pappot H, Rønne E, Danø K, Klijn JGM, Brünner N, Foekens JA: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1: 1079-1087, 1995
9. Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, Jänicke F, Graeff H: Prognostic value of the cysteine proteases cathepsin B and cathepsin L in human cancer. Clin Canc Res 1: 741-746, 1995
10. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Günzler WA, Jänicke F, Graeff H: Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem 266: 5147-5152, 1991
11. DeClerk YE, Laug WE: Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. In: Plasminogen Activators and their Inhibitors, Enzyme Protein 1996; 49: 72-84, Karger, Basel
12. Carmeliet P, Collen D: Evaluation of the plasminogen/plasmin system in transgenic mice. Fibrinolysis 8: 269-276, 1994
13. Kute T, Huste MS, Shore A, Rhyne A: Improvements in steroid receptor assays including rapid computer analysis of data. Anal Biochem 130: 272-279, 1980
14. Rosenquist C, Thorpe SM, Danø K, Grøndahl-Hansen J: Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res Treat 28: 223-229, 1993
15. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
16. Cox D: Regression models and life tables (with discussion). J R Stat Soc B 34: 87-202, 1972
17. Nomura Y, Miura S, Koyama H, Enomoto K, Kasumi F, Yamamoto H, Kimura M, Tominaga T, Iino H, Morimoto T, Tashiro H: Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. Cancer 69: 153-164, 1992
18. Garcia M, Derocq D, Pujol P, Rochefort H: Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 5: 1809-1814, 1990
19. Briozzo P, Morisset F, Capony C, Rougeot C, Rochefort H: In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res 48: 3688-3692, 1988
20. Ravdin PM: Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 24: 219-226, 1993
21. Rochefort H: The prognostic value of cathepsin D in breast cancer. A long road to the clinic (Editorial). Eur J Cancer 32A: 7-8, 1996
22. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82: 1006-1015, 1990